Aurora and Vectura Fertin Pharma Collaborate on CBD Lozenge for Canadian Medical Cannabis Market

We are happy to announce that Vectura Fertin Pharma, Inc., a leader in wellness and healthcare, and Aurora Cannabis, a well-known Canadian medical cannabis company, have partnered on a business venture. Cogent International Manufacturing Ltd. ("Cogent") is a fully-owned subsidiary of Vectura Fertin Pharma Inc. As a result of this agreement, Cogent will first offer its recently created CBD lozenge on Aurora's Canadian medical cannabis patient platform. This will allow Cogent to gather patient feedback, which will be utilised to verify the product's benefits and gauge how well patients react to it while also accumulating actual patient data for later research. The two businesses may investigate prospects for the possible commercialisation of more Vectura Fertin Pharma medicinal cannabis products in Canada after the CBD lozenge's successful launch.

"We are excited about this commercial collaboration that will allow Aurora to leverage its industry-leading patient platform in Canada to support advancements in medical cannabis, as well as to provide our patients with access to Vectura Fertin Pharma's new CBD lozenge," said Miguel Martin, Aurora's chief executive officer. "As a global leader in the manufacturing of pharmaceutical-grade medical cannabis, we are pleased to see increased interest in the possibilities of medical cannabis as part of healthcare options made available to Canadians."

"At Vectura Fertin Pharma, we are committed to building a pipeline of innovation, based on scientific rigour, to improve unmet medical and health needs," stated Michael Kunst, the company's CEO. We are thrilled to collaborate with the Aurora team, as they share our strict adherence to quality and safety standards as well as our unwavering commitment to enhancing the lives of people. By means of this tactical partnership, the Aurora platform will facilitate the distribution of our recently developed CBD lozenge—as recommended by a medical practitioner—to the broadest patient population in Canada. Additionally, it will allow us to conduct impact analyses and validate the product proposition by generating actual patient data."